At EDGE 2026 in Sydney, David A. Sinclair explores the scientific, economic and societal implications of longevity research. Moving beyond the idea of simply extending lifespan, he reframes aging as a treatable biological process and outlines how targeting aging itself could delay or prevent multiple diseases simultaneously.

Drawing on decades of research, Sinclair presents evidence that aging can be reversed in animal models and discusses how advances in epigenetics and AI-driven drug discovery are accelerating the path toward human clinical applications. The session challenges leaders to rethink medicine, productivity and economic growth in a world where lifespan and healthspan may soon be programmable.

KEY TAKEAWAYS
• Extending healthspan, not just lifespan, will redefine medicine, productivity and leadership planning
• Aging is positioned as a treatable biological process rather than an inevitable decline
• Longevity breakthroughs could generate multi-trillion-dollar economic impact